Trial · NCT07557498
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant blood pressure (both systolic and diastolic) | Baseline | Group 1 only |
| Primary | Date of diagnosis of hypertrophic cardiomyopathy | Baseline | Group 1 only |
| Primary | Hypertrophic cardiomyopathy genetic testing results | Baseline | Group 1 only |
| Primary | Family history of hypertrophic cardiomyopathy | Baseline | Group 1 only |
| Primary | Family history of Sudden Cardiac Death (SCD) | Baseline | Group 1 only |
| Primary | Participant comorbidities (cardiovascular and non-cardiovascular ) | Baseline | Group 1 only |
| Primary | Type of prior surgeries and procedures | Baseline and up to week 24 | Group 1 only. Prior surgeries and procedures include: Septal Reduction Therapy (SRT), surgeries (valve repair/placement, left atrial appendage ligation), placement of devices (Implantable Cardioverter Defibrillator (ICD), pacemaker and cardiac resynchronization therapy) or atrial fibrillation/flutter ablation |
| Primary | Participant New York Heart Association (NYHA) class category | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Change in participant New York Heart Association (NYHA) class from baseline | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Duration of mavacamten treatment | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Number of mavacamten dose titrations | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Type of mavacamten dose tritration | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Clinical reason for mavacamten dose titration | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Clinical reason for mavacamten treatment discontinuation | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%, | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Clinical reason for temporary mavacamten treatment interuption | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Time to temporary mavacamten treatment interruption | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50% | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07557498/registered